Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2010003025) BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2010/003025 International Application No.: PCT/US2009/049453
Publication Date: 07.01.2010 International Filing Date: 01.07.2009
IPC:
C07D 231/56 (2006.01) ,C07D 275/04 (2006.01) ,C07D 403/12 (2006.01) ,C07D 405/12 (2006.01) ,C07D 471/04 (2006.01) ,A61K 31/437 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
231
Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
54
condensed with carbocyclic rings or ring systems
56
Benzopyrazoles; Hydrogenated benzopyrazoles
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
275
Heterocyclic compounds containing 1, 2-thiazole or hydrogenated 1,2-thiazole rings
04
condensed with carbocyclic rings or ring systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
405
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
02
containing two hetero rings
12
linked by a chain containing hetero atoms as chain links
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
4353
ortho- or peri-condensed with heterocyclic ring systems
437
the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
HEALD, Robert, Andrew [GB/GB]; GB (UsOnly)
JACKSON, Philip [GB/GB]; GB (UsOnly)
LYSSIKATOS, Joseph [US/US]; US (UsOnly)
PRICE, Stephen [GB/GB]; GB (UsOnly)
SAVY, Pascal, Pierre [FR/GB]; GB (UsOnly)
GENENTECH, INC. [US/US]; 1 Dna Way South San Francisco, CA 94080-4990, US (AllExceptUS)
Inventors:
HEALD, Robert, Andrew; GB
JACKSON, Philip; GB
LYSSIKATOS, Joseph; US
PRICE, Stephen; GB
SAVY, Pascal, Pierre; GB
Agent:
WANG, Min; US
Priority Data:
61/077,42601.07.2008US
Title (EN) BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS
(FR) HÉTÉROCYCLES BICYCLIQUES EN TANT QU'INHIBITEURS DE MEK KINASE
Abstract:
(EN) The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
(FR) L'invention concerne des hétérocycles bicycliques des formules I et II avec une activité anticancéreuse et/ou anti-inflammatoire, et plus particulièrement une activité d'inhibition de MEK kinase. L'invention concerne des compositions et des procédés utiles pour inhiber une croissance cellulaire anormale, pour traiter un trouble hyper prolifératif, ou pour traiter une maladie inflammatoire chez un mammifère. L'invention concerne également des procédés d'utilisation des composés pour un diagnostic ou un traitement in vitro, in situ et in vivo, de cellules de mammifère ou d'états pathologiques associés.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)